Related Experiment Video
Updated: May 15, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Recent progress in conventional and biologic therapy for systemic lupus erythematosus
1Division of Rheumatology, The Rosalind Russell Medical Research Center for Arthritis at the University of California San Francisco, San Francisco, CA 94143, USA. wofsyd@medsch.ucsf.edu
Annals of the Rheumatic Diseases
|December 21, 2012
Summary
Belimumab is now approved for systemic lupus erythematosus (SLE), marking a new era for biologic therapies. Advances in conventional SLE treatments provide a benchmark for evaluating these novel biologic options.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) treatment has seen limited advancements until recently.
- A decade of optimism for biologic therapies in SLE has culminated in the approval of belimumab.
- Conventional SLE therapies have seen steady progress in understanding and application.
Purpose of the Study:
- To provide a frame of reference for evaluating novel biologic therapies for SLE.
- To contextualize the significance of belimumab's approval within the broader landscape of SLE treatment.
- To highlight the importance of conventional therapy advancements in assessing new biologic treatments.
Main Methods:
- Review of recent advancements in SLE treatment.
- Analysis of the impact of belimumab's approval.
- Comparative assessment of biologic versus conventional SLE therapies.
Main Results:
- Belimumab approval signifies a breakthrough in biologic therapy for SLE.
- Progress in conventional SLE therapies offers a baseline for comparison.
- The emergence of novel biologic therapies is anticipated.
Conclusions:
- The approval of belimumab marks a significant milestone in SLE treatment.
- Understanding conventional therapy progress is crucial for evaluating new biologics.
- The future of SLE management likely involves a combination of established and novel therapeutic approaches.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...